Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $3.1 million.

  • Voyager Therapeutics' Non-cash Items fell 1621.41% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 1621.41%. This contributed to the annual value of $4.8 million for FY2024, which is 2653.41% up from last year.
  • Latest data reveals that Voyager Therapeutics reported Non-cash Items of $3.1 million as of Q3 2025, which was down 1621.41% from $247000.0 recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Non-cash Items peaked at $29.9 million during Q2 2023, and registered a low of $247000.0 during Q2 2025.
  • Its 5-year average for Non-cash Items is $5.6 million, with a median of $3.8 million in 2024.
  • Per our database at Business Quant, Voyager Therapeutics' Non-cash Items surged by 42317.6% in 2022 and then tumbled by 9739.48% in 2025.
  • Voyager Therapeutics' Non-cash Items (Quarter) stood at $1.2 million in 2021, then soared by 423.18% to $6.1 million in 2022, then plummeted by 37.27% to $3.8 million in 2023, then increased by 26.53% to $4.8 million in 2024, then tumbled by 34.95% to $3.1 million in 2025.
  • Its Non-cash Items stands at $3.1 million for Q3 2025, versus $247000.0 for Q2 2025 and $499000.0 for Q1 2025.